Eesti -
eesti -
Ravimiamet
pre-pen skin test antigen süstelahus
allerquest llc - bensüülpenitsilloüülpolülüsiin - süstelahus - 0,25ml 5tk
Eesti -
eesti -
Ravimiamet
inmunotek skin prick test naha torketesti lahus
inmunotek s.l. - allergiliste haiguste testid - naha torketesti lahus - 2.5ml 1tk
Eesti -
eesti -
Ravimiamet
allergen extract for skin prick testing naha torketesti lahus
allergy therapeutics (uk) ltd - allergiliste haiguste testid - naha torketesti lahus - 2ml 1tk
Eesti -
eesti -
Ravimiamet
seclaris dc intramammaarsuspensioon
ceva sante animale - tsefaloonium - intramammaarsuspensioon - 250mg 3g 3g 72tk; 250mg 3g 3g 20tk
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
tecvayli
janssen-cilag international n.v. - teclistamab - mitu müeloomit - antineoplastilised ained - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - muud antineoplastilised ained - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
ebvallo
pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.